



ASX ANNOUNCEMENT

20 December 2022

Cleansing Statement

[CardieX Limited](#) (ASX: CDX) (**CardieX**, the **Company**) advises that on 16 December 2022, it issued a total of 3,452,329 Fully Paid Ordinary Shares without disclosure to the recipients under Part 6D.2 of the Corporations Act 2001 (Cth) (the **Corporations Act**). On the same date, the Company also issued 11,355,814 unquoted securities.

The Company hereby gives notice under Section 708A(5) of the Corporations Act, and for all other purposes, that:

- (a) the company has issued the Securities without disclosure to the recipients under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, the Company has complied with the provisions of:
 - a. Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
- (c) As at the date of this notice there is no information
 - a. That has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. That investors and their professional advisers would reasonably require for the purpose of making an information assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
 - ii. the rights and liabilities attaching to the relevant securities.

to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

Approved by the Board of Directors and Released by Jarrod White, Director.

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger

Managing Director, Integrous Communications

mselinger@integcom.com

About CardieX

CardieX is a global health technology company. Its [ATCOR](#) subsidiary is a world leader in medical devices for hypertension, cardiovascular disease, and other vascular health disorders based on the Company's "gold standard" SphygmoCor® central blood pressure technology. CardieX's [CONNEQT](#) subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels. CardieX is listed on the Australian Stock Exchange (ASX:CDX).